Randomised controlled trials for COVID-19: evaluation of optimal randomisation methodologies-need for data validation of the completed trials and to improve ongoing and future randomised trial designsCOVID-19에 대한 무작위 대조 시험: 최적의 무작위화 방법론 평가 - 완료된 시험의 데이터 검증 및 진행 중인 및 미래의 무작위 시험 설계 개선 필요Review Published on 2021-01-012022-09-11 Journal: International journal of antimicrobial agents [Category] 임상, [키워드] (coronavirus disease 2019 benefit Controlled trial coronavirus disease Coronavirus disease 2019 COVID-19 Dexamethasone disease severity group Guidance HCQ Health Organization high mortality hospitalised COVID-19 patient Hydroxychloroquine IMPROVE Lopinavir Lopinavir/ritonavir methodology Metrics Mortality NIH Ordinal Scale outcomes pandemic patients randomisation randomised controlled trial Randomised trial RCT RCTs recovery RECOVERY trial reduced Remdesivir risk reduction Ritonavir sampling errors seven-point ordinal scale severity solidarity the disease Time to recovery treat Treatment Trial trials utilised WHO World Health Organization [DOI] 10.1016/j.ijantimicag.2020.106222 PMC 바로가기 [Article Type] Review
Global Safety Database Summary of COVID-19-Related Drug Utilization-Safety Surveillance: A Sponsor’s PerspectiveCOVID-19 관련 약물 사용-안전 감시의 글로벌 안전 데이터베이스 요약: 후원자의 관점Observational Study Published on 2021-01-012022-09-11 Journal: Drug safety [Category] 임상, 치료제, [키워드] activity adverse event Antibiotics Anticoagulant Anticoagulants antimalarial association Azithromycin ceftriaxone characterized Chloroquine chloroquine/hydroxychloroquine Clinical data collected conditions coronavirus disease Coronavirus disease 2019 Corticosteroids COVID-19 COVID-19 case COVID-19 cases COVID-19 treatment database diarrhea Dictionary drug drug interaction electrocardiogram event events followed by Hepatitis Hydroxychloroquine Immunoglobulin immunomodulating agents Immunosuppressant immunosuppressive effect immunosuppressive effects include individual Infection interferons lAbel Lopinavir Lopinavir-ritonavir MedDRA off-label over Pfizer provide QT prolongation receiving reported retrospective Ritonavir Safety Seven subsequent Surveillance term therapeutic therapy Tofacitinib Torsade de Pointes treated treated patients Treatment unique were used [DOI] 10.1007/s40264-020-01035-x PMC 바로가기 [Article Type] Observational Study
Evaluating the effects of Intravenous Immunoglobulin (IVIg) on the management of severe COVID-19 cases: A randomized controlled trial중증 COVID-19 사례 관리에 대한 정맥 면역글로불린(IVIg)의 효과 평가: 무작위 대조 시험Randomized Controlled Trial Published on 2021-01-012022-09-11 Journal: International immunopharmacology [Category] SARS, 임상, 진단, 치료제, [키워드] Admission both groups Combination control group coronavirus coronavirus disease Coronavirus disease 2019 COVID-19 demographic data dose Effect Evaluating Factors group hospital Hospital admission Hospital stay Hydroxychloroquine ICU Immunoglobulin Infection intensive care unit intervention group Intravenous immunoglobulin IVIG Lopinavir Lopinavir/ritonavir management mechanical ventilation Mortality mortality rate no significant difference P-value pandemic Patient positive positive relationship Previous studies previous study pulmonary Pulmonary infection Pulmonary infection. Randomized controlled trial reducing Ritonavir severe cases severe COVID-19 significantly lower Support supportive care survivor Treatment two group two groups Viral Viral load were recorded [DOI] 10.1016/j.intimp.2020.107205 PMC 바로가기 [Article Type] Randomized Controlled Trial
Comparison of the Efficacy and Safety of Atazanavir/Ritonavir Plus Hydroxychloroquine with Lopinavir/Ritonavir Plus Hydroxychloroquine in Patients with Moderate COVID-19, A Randomized, Double-blind Clinical TrialOriginal Article Published on 2021-01-012022-10-30 Journal: Iranian Journal of Pharmaceutical Research : IJPR [Category] COVID-19, [키워드] Admission Adverse reaction analyzed assigned Atazanavir clinical Clinical outcome clinical recovery clinical trial Coronavirus disease 2019 COVID-19 discharged double-blind Efficacy Efficacy and safety enrolled Frequency groups HCQ Hospital stay Hydroxychloroquine ICU ICU admission intensive care Intervention Intubated intubation Lopinavir Lopinavir/ritonavir median moderate Mortality nausea participant patients Primary outcome Randomized Randomly receive reduced reported Safety Secondary outcomes single dose statistically vomiting [DOI] 10.22037/ijpr.2021.115157.15243 PMC 바로가기 [Article Type] Original Article
Molecular screening of antimalarial, antiviral, anti-inflammatory and HIV protease inhibitors against spike glycoprotein of coronavirus코로나바이러스의 스파이크 당단백질에 대한 항말라리아제, 항바이러스제, 항염증제 및 HIV 프로테아제 억제제의 분자 스크리닝Article Published on 2021-01-012022-09-11 Journal: Journal of molecular graphics & modelling [Category] SARS, 신약개발, 치료제, [키워드] ACE2 receptor ACE2 receptor binding Amino acid Analysis Anti-inflammatory anti-inflammatory drug Anti-inflammatory drugs antibiotic antibiotic drug antibiotic drugs antimalarial antimalarial drug Antimalarial drugs Antiviral antiviral drug target antiviral drugs applied Artemisinin Baricitinib Chloroquine Clinical studies clinical study Cobicistat coronavirus CoV COVID-19 darunavir docking docking score drug Efficacy and safety erythromycin glycoprotein H-bonds help high mortality rate HIV protease inhibitor homology modeling host cell host cells Human Hydroxychloroquine immunogenic inhibitor inhibitors interactions lead Lopinavir methodology molecular docking outbreak pharmacological preclinical studies preclinical study Protein Ritonavir ruxolitinib screened spike spike glycoprotein Spike protein Spiramycin thalidomide the patient therapeutic Treatment Treatment strategies Viral viral disease viral entry Virtual screening [DOI] 10.1016/j.jmgm.2020.107769 PMC 바로가기 [Article Type] Article
A systematic review on treatment-related mucocutaneous reactions in COVID-19 patientsCOVID-19 환자의 치료 관련 점막 피부 반응에 대한 체계적인 검토Article Published on 2021-01-012022-09-11 Journal: Dermatologic therapy [Category] SARS, 치료제, [키워드] Adverse drug reaction Adverse drug reactions adverse effect adverse effects Adverse reaction AGEP Anti-viral antibiotic Antibiotics antimalarial antimalarial drug Antimalarial drugs Antiviral article articles Azithromycin Better biologic clinical trials cohorts Combination Corona virus coronavirus COVID-19 COVID-19 patient covid-19 therapies COVID-19 treatments Cutaneous cutaneous drug reactions database databases Dermatology drug drug eruption drug eruptions drug induced drug reaction drug usage enoxaparin eruption Favipiravir Frequency HCQ highest human coronavirus Hydroxychloroquine induce initial Jak JAK inhibitor Janus kinase Janus kinase inhibitor Kinase inhibitor less Lopinavir Lopinavir/ritonavir maculopapular rashe maculopapular rashes management MOST mucocutaneous mucosal novel human coronavirus (SARS-CoV-2) occur pandemic potentially life-threatening prevalent rashes reaction Reactions Ritonavir Side effect Side effects skin skin reactions steroid Steroids syndrome systematic review targeted therapy TNF-α TNF-α inhibitor Tocilizumab Treatment treatment-induced treatment-reaction treatment-related. Type Usage Vasculitis [DOI] 10.1111/dth.14662 PMC 바로가기 [Article Type] Article
Comparison of antiviral effect for mild-to-moderate COVID-19 cases between lopinavir/ritonavir versus hydroxychloroquine: A nationwide propensity score-matched cohort study로피나비르/리토나비르 대 히드록시클로로퀸 간의 경증 내지 중등도 COVID-19 사례에 대한 항바이러스 효과 비교: 전국적인 성향 점수 일치 코호트 연구Comparative Study Published on 2021-01-012022-09-11 Journal: International Journal of Infectious Diseases [Category] SARS, 치료제, [키워드] age Analysis Antiviral effect benefit case-control study cohort study conducted control group control groups controls COVID-19 COVID-19 case determine HCQ Health Insurance Hydroxychloroquine insurance IQR Lopinavir Lopinavir/ritonavir malignancy median Mild-to-moderate Multivariate analysis National Health Insurance not significantly different old age Patient patients with COVID-19 Pneumonia prolonged viral shedding propensity score matching PSM retrospective risk factor Ritonavir SARS-CoV-2 service standard care statistically significant steroid steroid use three groups treatment groups Viral viral clearance viral shedding [DOI] 10.1016/j.ijid.2020.10.062 PMC 바로가기 [Article Type] Comparative Study
Pentoxifylline: A Drug with Antiviral and Anti-Inflammatory Effects to Be Considered in the Treatment of Coronavirus Disease 2019Pentoxifylline: 코로나바이러스 질병 2019의 치료에 고려되는 항바이러스 및 항염 효과가 있는 약물Article Published on 2021-01-012022-09-11 Journal: Medical principles and practice : international jo [Category] SARS, 치료제, [키워드] activate acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 adenosine adenosine monophosphate Anti-inflammatory can not caused China Chloroquine coronavirus coronavirus disease Coronavirus disease 2019 Coronavirus-2 COVID-19 cyclic adenosine monophosphate Cytokines disease drug Effect Effects Efficacy elevated Favipiravir feasible Immune cell Immunological studies Immunological study immunomodulatory in vitro increase inhibit inhibitor Lopinavir Migration monophosphate Most patients New coronavirus outbreak Patient patients Pentoxifylline Pneumonia pro-inflammatory cytokine pro-inflammatory cytokines Protein protein kinase reduction in Remdesivir respiratory ribavirin Ritonavir SARS-CoV-2 Serum level severe acute respiratory syndrome Coronavirus severe acute respiratory syndrome coronavirus-2 severe COVID-19 shown Spread synthesis the disease Toxicity treatment for COVID-19 turn Viral viral infections virus Wuhan [DOI] 10.1159/000512234 PMC 바로가기 [Article Type] Article
Prognostic factors and predictors of outcome in patients with COVID-19 and related pneumonia: a retrospective cohort studyCOVID-19 및 관련 폐렴 환자의 예후 인자 및 예후 인자: 후향적 코호트 연구Virology Published on 2020-12-232022-09-10 Journal: Bioscience Reports [Category] MERS, 치료제, [키워드] ACE-inhibitors adopted Affect Anticoagulant treatment baseline Brescia Cancer cardiovascular risk factor cardiovascular risk factors chronic obstructive chronic obstructive pulmonary disease clinical benefit co-morbidity consecutive patient COVID-19 death demonstrated Dexamethasone diabetes died discharge disease dose drugs enoxaparin Factor Follow-up heart disease Hospital admission Hospitalization Hydroxychloroquine hypertension in some In-hospital Italy Lopinavir morbidities morbidity obstructive pulmonary disease once daily outcome patients patients died patients with COVID-19 Pneumonia predictor Prognosis pulmonary disease radiologic Respiratory failure retrospective cohort study risk of death Ritonavir SARS-CoV-2 SARS-CoV2 survival Tocilizumab treated Treatment treatment with tocilizumab variable were assessed worse prognosis [DOI] 10.1042/BSR20203455 PMC 바로가기 [Article Type] Virology
Retrospective analysis of severe COVID-19 pneumonia patients treated with lopinavir/ritonavir: A comparison with survivor and non-survivor patientsOriginal Research Published on 2020-12-212022-10-28 Journal: Southern African Journal of Infectious Diseases [Category] COVID-19, [키워드] 1.26 95% confidence interval advanced age affecting age analysed Analysis arrhythmia Aspartate transaminase AST C-reactive protein C-reactive protein (CRP changes in comorbid disease Comorbidity congestive heart failure Coronary artery disease COVID-19 D-dimer determine diabete diabetes disease Efficacy Factor female hypertension increased mortality Laboratory lactate dehydrogenase LDH Lopinavir male Mortality neutrophil non-survivor Patient patients patients treated Result Ritonavir Severe COVID-19 pneumonia severe pneumonia smoking statistically survivor treated treatment for COVID-19 [DOI] 10.4102/sajid.v35i1.233 PMC 바로가기 [Article Type] Original Research